Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection

Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection

Background. Lung transplant recipients (LTRs) have an increased risk of COVID-19–related morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal antibody combination granted Emergency Use Authorization approval by the US Food and Drug Administration for COVID-19 pre-exp...

Full description

Bibliographic Details
Main Authors: Devika Sindu, MD, Deepika Razia, MD, Katherine Grief, RN, MSN, Lauren Cherrier, MD, Ashraf Omar, MD, Rajat Walia, MD, Sofya Tokman, MD
Format: Article
Language:English
Published: Wolters Kluwer 2023-06-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001485

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001485

Similar Items